Terns Pharmaceuticals (NASDAQ:TERN) Earns "Neutral" Rating from HC Wainwright
HC Wainwright reissued their neutral rating on shares of Terns Pharmaceuticals (NASDAQ:TERN – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a $5.50 price target on the stock. A number of other research analysts have also commented on TERN. JMP Securities decreased their price target on […]